Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Merck & Company, Inc. (NYSE:MRK) by 2.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,096,712 shares of the company’s stock after purchasing an additional 158,794 shares during the quarter. Merck & comprises about 0.8% of Sumitomo Mitsui Trust Holdings Inc.’s portfolio, making the stock its 26th biggest position. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.30% of Merck & worth $518,918,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of the stock. Perennial Advisors LLC increased its holdings in Merck & by 10.7% during the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock worth $104,000 after purchasing an additional 157 shares in the last quarter. Stelac Advisory Services LLC bought a new stake in Merck & during the 2nd quarter worth approximately $104,000. Vigilant Capital Management LLC increased its holdings in Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after purchasing an additional 250 shares in the last quarter. Cascade Investment Advisors Inc. grew its holdings in shares of Merck & by 15.5% in the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares in the last quarter. Finally, Solaris Asset Management LLC grew its holdings in shares of Merck & by 6.3% in the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after acquiring an additional 115 shares in the last quarter. 73.15% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/11/13/merck-company-inc-mrk-stake-lifted-by-sumitomo-mitsui-trust-holdings-inc.html.
In related news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.25% of the stock is owned by corporate insiders.
Several equities analysts recently commented on the company. Cowen and Company reiterated a “hold” rating and issued a $70.00 price objective on shares of Merck & in a research note on Friday, November 3rd. Berenberg Bank reiterated a “hold” rating on shares of Merck & in a research note on Wednesday, November 1st. Jefferies Group LLC downgraded Merck & from a “hold” rating to an “underperform” rating in a research note on Wednesday, November 1st. BMO Capital Markets set a $68.00 price objective on Merck & and gave the company a “buy” rating in a research note on Monday, October 30th. Finally, Leerink Swann dropped their price objective on Merck & from $70.00 to $69.00 and set a “market perform” rating on the stock in a research note on Monday, October 30th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $67.07.
Shares of Merck & Company, Inc. (NYSE MRK) opened at $55.48 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. Merck & Company, Inc. has a 12-month low of $54.41 and a 12-month high of $66.80. The stock has a market capitalization of $151,151.77, a price-to-earnings ratio of 14.26, a P/E/G ratio of 2.39 and a beta of 0.78.
Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The company had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. During the same quarter last year, the business posted $1.07 earnings per share. The firm’s revenue was down 2.0% compared to the same quarter last year. analysts expect that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.